Drug Trial News

RSS

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

12 Dec 2022

$Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction$

Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction

AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin in Great Britain for the treatment of symptomatic chronic heart failure (HF) in patients with HF and a left ventricular ejection fraction (LVEF) >40%, including HF with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF).

From AstraZeneca 12 Dec 2022

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Researchers from the University of Pennsylvania's Abramson Cancer Center presented preliminary results of an ongoing Phase I clinical trial demonstrating successful re-treatment with CAR T cell therapy for patients whose cancers relapsed after previous CAR T therapy at the 2022 American Society of Hematology Annual Meeting.

12 Dec 2022

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

12 Dec 2022

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.

12 Dec 2022

Intranasal recombinant MVA-based vaccines effective against SARS-CoV-2 variants in mice

Researchers construct a recombinant host-range restricted vaccinia virus Ankara (rMVAs) expressing the spike proteins of several SARS-CoV-2 variants.

11 Dec 2022

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

9 Dec 2022

Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial

The George Washington University Vaccine Research Unit in partnership with Scripps Research, IAVI, Fred Hutchinson Cancer Center (FHCC) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases Vaccine Research Center published the results of their Phase 1 Clinical Trial in Science.

8 Dec 2022

Updated results on a new approach to treating advanced ER-positive/HER2-negative breast cancer

A UCLA Jonsson Comprehensive Cancer Center researcher and collaborators in a multicenter study will present updated results and plans for further research on a new approach to treating advanced ER-positive/HER2-negative breast cancer.

7 Dec 2022

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Vaccine MVA-BN shows consistent, robust immunogenicity and safety results

A phase III clinical trial showed consistent immunogenicity for a freeze-dried formulation of Bavarian Nordic's Modified Vaccinia Ankara.

5 Dec 2022

Trial assesses the impact of two immunomodulators in reducing CV risk among rheumatoid arthritis patients

People with rheumatoid arthritis are at increased risk of cardiovascular (CV) disease, with studies indicating an approximate 50 percent increase in risk of CV events such as heart attack and stroke.

5 Dec 2022

New trial to evaluate a potential treatment for irritability in teenagers with autism

A new trial will test whether a medication that targets gut bacteria can also improve irritability in teenagers with autism spectrum disorder.

5 Dec 2022

Trial shows acoziborole drug clears body of African sleeping sickness parasites

Researchers evaluate the efficacy and safety of an oral antimicrobial drug acoziborole in patients with human African trypanosomiasis.

4 Dec 2022

The business of clinical trials is booming. Private equity has taken notice.

After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry's more hidden niches: They are pouring billions into the business of clinical drug trials.

2 Dec 2022

First-in-humans test provides promising results for a broadly neutralizing antibody HIV vaccine

A Phase 1 clinical trial provides promising results for a broadly neutralizing antibody (bnAb) HIV vaccine, according to a new study.

1 Dec 2022

Phase 2 clinical trial of DS-1211 begins for individuals with Pseudoxanthoma Elasticum

A Phase 2 clinical trial has started of DS-1211 in individuals with Pseudoxanthoma Elasticum (PXE), a rare multisystem genetic disease that causes calcium deposits in soft tissue resulting in considerable morbidity.

1 Dec 2022

Phase 2/3 clinical trial shows that Clover’s vaccine candidate reduces household transmission of SARS-CoV-2

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, and the International Vaccine Institute, an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, today announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

30 Nov 2022

Previous
1
...
39
40
41
42
43
44
45
...
1156
Next

Drug Trial News

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Intranasal recombinant MVA-based vaccines effective against SARS-CoV-2 variants in mice

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial

Updated results on a new approach to treating advanced ER-positive/HER2-negative breast cancer

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Vaccine MVA-BN shows consistent, robust immunogenicity and safety results

Trial assesses the impact of two immunomodulators in reducing CV risk among rheumatoid arthritis patients

New trial to evaluate a potential treatment for irritability in teenagers with autism

Trial shows acoziborole drug clears body of African sleeping sickness parasites

The business of clinical trials is booming. Private equity has taken notice.

First-in-humans test provides promising results for a broadly neutralizing antibody HIV vaccine

Phase 2 clinical trial of DS-1211 begins for individuals with Pseudoxanthoma Elasticum

Phase 2/3 clinical trial shows that Clover’s vaccine candidate reduces household transmission of SARS-CoV-2

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News